August 2020

IDIBELL scientists fins a new combination of drugs to treat rhabdomyosarcoma, a highly aggressive tumor in children

The chemoresistance group of IDIBELL and ICO’s ProCURE Program, led by Alberto Villanueva, has transferred its experience in generating orthotopic mouse models in adult patients to the pediatric field.

IDIBELL scientists fins a new combination of drugs to treat rhabdomyosarcoma, a highly aggressive tumor in children Read More »

Age and male sex, key factors in the risk of mortality after hospital admission due to COVID-19

A study with the participation of IDIBELL adds complete information on the complications and prognosis of the first 4,035 patients with COVID-19 in the country.

Age and male sex, key factors in the risk of mortality after hospital admission due to COVID-19 Read More »

A study determines the prevalence of mutations in two polymerases in patients with hereditary cancer

A team from the IDIBELL-ICO Hereditary Cancer group has studied more than 2,800 patients with a possible hereditary cancer to determine the frequency of pathogenic mutations in the corrective region of two polymerases.
Identifying these mutations can facilitate the early diagnosis and the personalized treatment of these patients.

A study determines the prevalence of mutations in two polymerases in patients with hereditary cancer Read More »

Scroll to Top